Aducanumab for Treatment of Alzheimer’s Disease: Controversy & Patient Communications
1.5 CMA PRA Category 1 Credits
This panel discussion among geriatric specialists will clarify controversial issues surrounding FDA’s recent approval of aducanumab for treatment of Alzheimer’s disease, and appropriate messaging to patients and family members. The presentation was filmed from the live July 21, 2021 webinar, and covers:
- Importance of early screening, and how to conduct
- Specific testing needed to be conducted prior to referral to administering practitioner
- Potential risks and side effects of aducanumab
- Other current clinical trials that may be appropriate
To access the webinar, click here!
